Do selective COX‐2 inhibitors increase the risk of cerebrovascular events? A meta‐analysis of randomized controlled trials

@article{Chen2006DoSC,
  title={Do selective COX‐2 inhibitors increase the risk of cerebrovascular events? A meta‐analysis of randomized controlled trials},
  author={L-C Chen and Darren M. Ashcroft},
  journal={Journal of Clinical Pharmacy and Therapeutics},
  year={2006},
  volume={31}
}
Objectives:  To evaluate the risk of cerebrovascular events (CVEs) associated with selective cyclooxygenase‐2 inhibitors (coxibs). 
Use of non‐steroidal anti‐inflammatory drugs and risk of ischemic and hemorrhagic stroke in the Australian veteran community
TLDR
The association between the use of non‐selective ns‐NSAIDs, selective COX‐2 inhibitors, or either of these NSAIDs, and the incidence of stroke‐related hospitalization in elderly subjects is studied. Expand
Cardiovascular risk and inhibition of cyclooxygenase: traditional nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors
TLDR
This review confirms the findings from randomized trials, meta-analysis and observational studies regarding the risk of cardiovascular events with rofecoxib, valdecoxib e parecoxib, whereas the evidence for other COXIBs is not so clear. Expand
Cardiovascular and Gastrointestinal Safety of NSAIDs: A Systematic Review of Meta‐Analyses of Randomized Clinical Trials
TLDR
The authors' systematic review of MAs included information on the incidence of CV and GI events and identified important knowledge gaps regarding, in particular, the CV safety of traditional NSAIDs. Expand
Risk of stroke associated with nonsteroidal anti-inflammatory drugs
TLDR
The relevant literature assessing the possible association between NSAID use and stroke events is discussed, along with the potential mechanisms and the possible directions for future study. Expand
Cardiovascular and cerebrovascular risk with nonsteroidal anti-inflammatory drugs and cyclooxygenase 2 inhibitors: latest evidence and clinical implications
TLDR
Prescription of the right drug based on the patient’s features and the different safety profiles of several NSAIDs that are available on the market is key for their appropriate administration. Expand
Cerebrovascular Events After Discontinuation of Rofecoxib Treatment
TLDR
The finding of an excess of thrombotic cardiovascular events, primarily of myocardial infarction, in the VIGOR trial raised concern about the cardiovascular safety of rofecoxib, and also of COX-2 inhibitors in general. Expand
Data sources on drug safety evaluation: a review of recent published meta‐analyses
TLDR
This study aims to identify and analyze meta‐analyses from both ES and OS where safety was found to be an outcome measure. Expand
NSAIDs and stroke risk
  • D. Blacker
  • Medicine
  • The Medical journal of Australia
  • 2011
The Medical Journal of Australia ISSN: 0025729X 7 November 2011 195 9 488-488 ©The Medical Journal of Australia 2011 www.mja.com.au Editorials different NSAID classes. The population studied by CExpand
Emerging roles of PGE2 receptors in models of neurological disease.
  • K. Andreasson
  • Biology, Medicine
  • Prostaglandins & other lipid mediators
  • 2010
TLDR
This review presents an overview of the emerging field of prostaglandin signaling in neurological diseases, focusing on PGE(2) signaling through its four E-prostanoid (EP) receptors, where cerebroprotective or toxic effects of a particular prostaglandsin signaling pathway can differ depending on the context of cerebral injury. Expand
Efficacy and safety of selective COX-2 inhibitors for pain management after third molar removal: a meta-analysis of randomized clinical trials
TLDR
COX-2 inhibitors could be considered a suitable alternative to ibuprofen for pain relief after third molar extraction in patients at risk of developing nausea and vomiting and seem to slightly reduce the need of rescue medication consumption. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 84 REFERENCES
Cardiovascular risk of selective cyclooxygenase‐2 inhibitors and other non‐aspirin non‐steroidal anti‐inflammatory medications
The purpose of this study was to estimate rates of acute coronary syndrome (ACS), and sudden cardiac death in relation to use of rofecoxib, celecoxib, naproxen, diclofenac, and ibuprofen.
Understanding the NSAID related risk of vascular events
TLDR
This review links biochemical facts concerning NSAIDs and COX inhibitors with data from clinical trials to show that a class effect might exist for selective COX 2 inhibitors. Expand
Monitoring the safety of licensed medicines
TLDR
The current mechanisms for post-marketing surveillance of drug safety are discussed, whether they are being used appropriately, and the need for changes to regulatory systems is considered. Expand
Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials
TLDR
Selective COX 2 inhibitors are associated with a moderate increase in the risk of vascular events, as are high dose regimens of ibuprofen and diclofenac, but high dose naproxen is not associated with such an excess. Expand
Learning the value of drugs--is rofecoxib a regulatory success story?
TLDR
This data indicates that continued use of these drugs after a number of adverse events may be a viable option for some patients, but the benefits and risks of these treatments are still limited. Expand
Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis.
TLDR
The available data indicate an increased risk of myocardial infarction with celecoxib therapy, consistent with a class effect for COX-2 specific inhibitors. Expand
Risk of cardiovascular events and rofecoxib: cumulative meta-analysis
TLDR
The findings indicate that rofecoxib should have been withdrawn several years earlier and the reasons why manufacturer and drug licensing authorities did not continuously monitor and summarise the accumulating evidence need to be clarified. Expand
Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac.
TLDR
The hypothesis of a class adverse effect of cyclooxygenase 2 specific inhibitors on the CV system is not supported and the incidences of adverse CV events such as hypertension, edema, and congestive heart failure were similar to, or significantly lower than, NSAID comparators regardless of the use of ASA. Expand
Risk Factors for Hospitalized Gastrointestinal Bleeding Among Older Persons
TLDR
Estimation of the incidence of hospitalization for upper and lower gastrointestinal bleeding among older persons and to identify independent risk factors is sought. Expand
Effects of the Cyclooxygenase-2 Specific Inhibitor Valdecoxib Versus Nonsteroidal Antiinflammatory Agents and Placebo on Cardiovascular Thrombotic Events in Patients with Arthritis
TLDR
Short- and intermediate-term treatment with therapeutic and supratherapeutic valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials. Expand
...
1
2
3
4
5
...